MedPath
HSA Approval

LEQEMBI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

SIN17228P

LEQEMBI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

LEQEMBI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

May 2, 2025

EISAI (SINGAPORE) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantEISAI (SINGAPORE) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

N06DX04

Manufacturer Information

EISAI (SINGAPORE) PTE. LTD.

Vetter Pharma-Fertigung GmbH & Co. KG

Biogen U.S. Corporation

Active Ingredients

Lecanemab

100 mg/ml

Lecanemab

Documents

Package Inserts

Leqembi final PI May 2025.pdf

Approved: May 2, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.